How big is Merus NV?

As of Jun 18, Merus NV has a market capitalization of 3,953.23 million, classifying it as a Small Cap company, with net sales of 54.73 million and a net profit of -277.34 million over the latest four quarters.

Market Cap: As of Jun 18, Merus NV has a market capitalization of 3,953.23 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Merus NV reported net sales of 54.73 million and a net profit of -277.34 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 647.93 million and total assets of 785.13 million.

What does Merus NV do?

Merus NV is a Netherlands-based biotechnology company focused on developing cancer therapeutics, with recent net sales of $26 million and a net loss of $96 million. It has a market cap of approximately $3.95 billion and operates as a small-cap company.

Overview: <BR>Merus NV is a biotechnology company based in the Netherlands that develops differentiating therapeutics for cancer patients, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 26 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -96 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,953.23 Million (Small Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.77 <BR>Return on Equity: -46.52% <BR>Price to Book: 6.63 <BR><BR>Contact Details: <BR>Address: Yalelaan 62, UTRECHT None: 3584 CM <BR>Tel: ['31 30 2538800', '1 617 9554716'] <BR>Website: https://www.merus.nl/

Who are in the management team of Merus NV?

As of March 2022, the management team of Merus NV includes Dr. Anand Mehra (Non-Executive Independent Chairman), Dr. Sven Lundberg (CEO), Mr. Gregory Perry (Independent Non-Executive Vice Chairman), and several Non-Executive Independent Directors: Mr. Mark Iwicki, Mr. Leonard Kanavy, and Mr. Paolo Pucci. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Merus NV includes the following individuals:<BR><BR>- Dr. Anand Mehra, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Dr. Sven Lundberg, who is the President, Chief Executive Officer, Principal Financial Officer, and Executive Director.<BR>- Mr. Gregory Perry, who is the Independent Non-Executive Vice Chairman of the Board.<BR>- Mr. Mark Iwicki, who is a Non-Executive Independent Director.<BR>- Mr. Leonard Kanavy, who is also a Non-Executive Independent Director.<BR>- Mr. Paolo Pucci, who serves as a Non-Executive Independent Director. <BR><BR>This team is responsible for guiding the strategic direction and governance of the company.

Should I buy, sell or hold Merus NV?

Is Merus NV overvalued or undervalued?

As of November 7, 2016, Merus NV is considered risky and overvalued due to its high Price to Book Value of 7.02, negative EV to EBIT and EV to EBITDA ratios, and a concerning ROCE of -215.67%, despite a strong year-to-date stock performance of 63.97%.

As of 7 November 2016, the valuation grade for Merus NV moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial health. The company appears to be overvalued, particularly given its high Price to Book Value of 7.02 and negative EV to EBIT and EV to EBITDA ratios of -12.39 and -12.49, respectively. Additionally, the Return on Capital Employed (ROCE) stands at a concerning -215.67%, further underscoring the challenges the company faces.<BR><BR>In comparison to its peers, Merus NV's EV to EBITDA ratio of -12.49 is less favorable than Arcellx, Inc. at -16.81 and CymaBay Therapeutics, Inc. at -34.09, suggesting that Merus is not performing as well as its competitors in the same industry. Despite this, the company has shown impressive stock performance, with a year-to-date return of 63.97%, significantly outpacing the S&P 500's 12.22% return during the same period. However, the overall financial metrics indicate that Merus NV is overvalued in the current market context.

Is Merus NV technically bullish or bearish?

As of September 11, 2025, Merus NV's technical trend is bullish, supported by positive MACD readings and a strong year-to-date return of 63.97%, significantly outperforming the S&P 500's 12.22%.

As of 11 September 2025, the technical trend for Merus NV has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish MACD readings on both weekly and monthly time frames, and a bullish daily moving average. However, the weekly and monthly RSI readings are bearish, indicating potential weakness. The Bollinger Bands show a mildly bullish trend weekly and bullish monthly, while the KST is bullish weekly but mildly bearish monthly. Dow Theory indicates a bullish monthly trend, but no trend on the weekly. The On-Balance Volume is mildly bullish on both time frames.<BR><BR>In terms of performance, Merus NV has outperformed the S&P 500 across multiple periods, with a year-to-date return of 63.97% compared to the S&P 500's 12.22%, and a three-year return of 208.09% versus 70.41% for the benchmark.